About us
The story of CellTolerance®
The CellTolerance® program is grounded in more than a decade of clinical research demonstrating the power of live cell response visualisation of barrier function. Some key milestones include:
2014
Initial patient enrollment and first publication1
2019
Expansion of clinical research and second publication2
2022
Clinical research presented at UEGW 2022
2023
More clinical research presented at DDW 2023 and UEGW 2023
2023
First 500 procedures completed globally
2024
More clinical research presented at DDW 2024
2024
First 1,000 procedures completed globally
2024
Global launch of multi-disciplinary CellTolerance® program
A revolutionary technology
Live cell-response visualisation.
CellTolerance® is powered by Cellvizio®, the real-time in vivo cellular imaging platform.
Cellvizio offers real-time, high-magnification visualization of cellular structures and functions, and this breakthrough technology empowers physicians to make better informed decisions across a wide range of medical specialties.
Cellvizio has been the subject of 1,100+ peer-reviewed publications and is utilized in hundreds of institutions around the world.
Cellvizio® software to visualize cell responses
Cellvizio® confocal laser probe
References
- 2014: Fritscher-Ravens A, Schuppan D, Ellrichmann M, et al. Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology 2014;147:1012-1020.e4. doi:10.1053/j.gastro.2014.07.046
- 2019: Fritscher-Ravens A, Pflaum T, Mösinger M, et al. Many Patients With Irritable Bowel Syndrome Have Atypical Food Allergies Not Associated With Immunoglobulin E. Gastroenterology 2019;157:109-118.e5. doi:10.1053/j.gastro.2019.03.046